Epizyme to Participate in Upcoming Conferences in May

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2012 - Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics, today announced its participation in five upcoming conferences.

 

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for patients with genetically-defined cancers, based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme's patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches. Epizyme has benchmark partnerships with Celgene, GSK and Eisai and receives funding and strategic support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS). www.epizyme.com

Contact: MacDougall Biomedical Communications
Kari Watson or Jennifer Conrad, 781-235-3060

 

Posted: May 2012

View comments

Hide
(web4)